Arkema to expand advanced biomaterials production capacity by 50% starting mid-2022

In France, Arkema announced a 50% global capacity expansion for its Oleris advanced biomaterials, expected to start mid-2022. It includes C7, C11 and C18 materials, comprising n-heptanoic acid, n-heptaldehyde, undecylenic acid and Esterol A. This new production capacity will be part of Arkema’s previously announced major bio-factory currently under construction on Jurong Island in Singapore.

For many years, Arkema has been the leader in advanced bio-based C7, C11 and C18 oleochemicals used extensively in the cosmetics, fragrances & flavors, lubricants, construction, and pharmaceutical markets. These specialty chemicals are 100% derived from renewable castor seeds. Oleris advanced bio-materials are recognized for their carbon-neutral footprint as well as for their high purity, broad compliance, and technical quality.

The new capacity is scheduled to come on-stream mid-2022 and will complement Arkema’s existing production in Marseille, France. This represents a step change in global supply assurance.